Abstract
Meeting abstracts The increased understanding of immunoregulatory receptor pathways is now offering promising opportunities for immunotherapeutic intervention, as exemplified by the success of anti-CTLA-4 antibody (Ab) Ipilimumab. More recently, an agonist Ab for the co-stimulatory receptor
Highlights
The increased understanding of immunoregulatory receptor pathways is offering promising opportunities for immunotherapeutic intervention, as exemplified by the success of anti-CTLA-4 antibody (Ab) Ipilimumab
Preclinical studies have well documented the therapeutic efficacy of glucocorticoid-induced TNF receptor (GITR) ligation using the agonist Ab DTA-1
As antiGITR immunotherapy is being translated into the clinic, understanding the mechanisms of therapeutic efficacy or failure is warranted, and will allow the identification of prognostic biomarkers and guide the design of combination therapies
Summary
The increased understanding of immunoregulatory receptor pathways is offering promising opportunities for immunotherapeutic intervention, as exemplified by the success of anti-CTLA-4 antibody (Ab) Ipilimumab. Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment An agonist Ab for the co-stimulatory receptor glucocorticoid-induced TNF receptor (GITR) has entered the clinical evaluation.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
